{"id":"W3092984943","doi":"10.1016/j.ahj.2020.10.052","title":"Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction","year":2020,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta; St. Michael's Hospital","funders":"CSL Behring","keywords":"Medicine; Placebo; Myocardial infarction; Internal medicine; Coronary artery disease; Randomized controlled trial; Multicenter trial; Stroke (engine); Cardiology; Cholesterol; Surgery; Pathology; Multicenter study","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03094018,0.004946127,0.005575001,0.001489479,0.003265242,0.003008758,0.003869983,0.00514623,0.01850852],"category_scores_gemma":[0.01825019,0.00325876,0.002510146,0.001344329,0.005030807,0.002203831,0.001734532,0.008453594,0.007018981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00160488,"about_ca_system_score_gemma":0.01124012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001098581,"about_ca_topic_score_gemma":0.002158146,"domain_scores_codex":[0.9825593,0.0110155,0.0009362541,0.002156855,0.002246521,0.001085518],"domain_scores_gemma":[0.992668,0.001668024,0.0009924354,0.0009568701,0.001319725,0.002394977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7720491,0.03522603,0.00739972,0.01679233,0.002569549,0.001007302,0.0009504886,0.003470996,0.01689051,0.02416988,0.02972537,0.08974864],"study_design_scores_gemma":[0.7660149,0.1128582,0.006964262,0.002337097,0.00218396,0.0003654665,0.0002027989,0.003194508,0.003146076,0.01068649,0.09177009,0.0002761318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.02339007,0.005433565,0.0145989,0.00295901,0.003015787,0.9398466,0.004408712,0.0003695613,0.005977957],"genre_scores_gemma":[0.03747304,0.002035858,0.02700534,0.004743994,0.0007587476,0.9239051,0.00128561,0.0000447282,0.002747529],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.03094018,"threshold_uncertainty_score":0.1636293,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02853460989701299,"score_gpt":0.3109898858539356,"score_spread":0.2824552759569225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}